Adimmune
國光生物科技股份有限公司
Adimmune is a Taiwan TWSE-listed biotechnology company; its most advanced asset is EV71 vaccine (Marketing authorization obtained, Prevention of enterovirus 71 infection), as of 2026-11-01.
Pipeline
| Asset | Target / mechanism | Stage | Indication | Region | Source date | Source |
|---|---|---|---|---|---|---|
| EV71 vaccine | — | Marketing authorization obtained | Prevention of enterovirus 71 infection | Macau | — | Company disclosure |
| Southern hemisphere quadrivalent influenza vaccine (Brazil program) | — | Resources shifted away from Brazil program | Prevention of influenza | Brazil | — | Company disclosure |
Key events
No verified events in the past twelve months.